Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
A U.S. research team has discovered a protein called Niemann-Pick C1 (NPC1), which they found was responsible for allowing Ebola virus to enter and replicate within cells.
Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protect against both rabies and the Ebola virus.
The spread of Dengue fever in northern Australia may be controlled by a bacterium that infects mosquitoes that harbor the virus, Australian and U.S. researchers report Aug. 25 in two papers published in the journal Nature.
Research published by two teams of Army scientists and collaborators has identified a cellular protein that plays a critical role in Ebola virus infection.
Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.
More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in MDA providing financial assistance for the start of the first Phase 2 placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, as a potential therapy for Duchenne muscular dystrophy.
In a new development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Molecular and cell biologists at the University of Virginia Health System have discovered new information about how the Ebola virus works that could eventually lead to new drug treatments for the deadly virus.
The ten studies in this special issue document the substantial and growing burden of dengue in the Americas, Africa and Asia, and the burden of a chikungunya outbreak in India.
Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.
France's Sanofi-Pasteur, the world's largest vaccine maker, said Friday it hopes to introduce a dengue vaccine in 2014 to some high-risk nations, AlertNet reports. The vaccine is in the last stage of clinical testing in Australia, and the company said it hopes to produce 100 million doses of the vaccine annually, according to the news agency.
Canadian investigators have shown that a species of ebolavirus from Zaire that is highly virulent in humans can replicate in pigs, cause disease, and be transmitted to animals previously unexposed to the virus.
The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.
Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.
The natural killer cells of our immune defense are activated for an extended period after the acute infection, which challenges the prevailing view that the elevation and activation of cells quickly pass.
Scientists from Thailand have successfully produced the world’s first dengue hemorrhagic fever vaccine and will allow the private sector improve it for the effective treatment of patients. The Thailand Ministry of Science and Technology has introduced the world’s first live attenuated dengue hemorrhagic fever vaccine.
NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.